Nordea Investment Management AB Purchases 911,843 Shares of Illumina, Inc. $ILMN

Nordea Investment Management AB raised its position in Illumina, Inc. (NASDAQ:ILMN) by 2,792.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 944,500 shares of the life sciences company’s stock after purchasing an additional 911,843 shares during the period. Nordea Investment Management AB’s holdings in Illumina were worth $124,145,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in ILMN. Capital World Investors boosted its position in shares of Illumina by 20.0% in the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after acquiring an additional 3,331,542 shares during the period. AQR Capital Management LLC increased its position in Illumina by 55.3% during the second quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock worth $313,290,000 after acquiring an additional 1,174,295 shares during the period. Edmond DE Rothschild Holding S.A. increased its position in Illumina by 140.1% during the second quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company’s stock worth $136,312,000 after acquiring an additional 833,750 shares during the period. Thrivent Financial for Lutherans raised its stake in Illumina by 1,558.0% in the 2nd quarter. Thrivent Financial for Lutherans now owns 728,755 shares of the life sciences company’s stock worth $69,528,000 after purchasing an additional 684,802 shares in the last quarter. Finally, Pacer Advisors Inc. acquired a new stake in Illumina in the 3rd quarter worth about $61,663,000. Institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

ILMN stock opened at $124.33 on Monday. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $155.53. The firm has a market cap of $19.01 billion, a P/E ratio of 22.81, a P/E/G ratio of 2.38 and a beta of 1.45. The company’s 50-day moving average price is $130.92 and its two-hundred day moving average price is $120.95.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the sale, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. This represents a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.17% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on ILMN. Stifel Nicolaus increased their target price on shares of Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Robert W. Baird set a $137.00 price target on shares of Illumina in a research report on Friday, February 6th. JPMorgan Chase & Co. cut their price target on Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. Zacks Research downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. Finally, UBS Group restated a “neutral” rating and set a $135.00 price objective on shares of Illumina in a research note on Friday, February 6th. Six research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $129.69.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.